Adaptimmune Therapeutics PLC (ADAP) Stock Price Up -1.8%
Adaptimmune Therapeutics PLC (NASDAQ:ADAP)’s share price rose 1.8% during mid-day trading on Monday . The company traded as high as $8.95 and last traded at $8.77. Approximately 654,097 shares changed hands during mid-day trading, an increase of 136% from the average daily volume of 277,270 shares. The stock had previously closed at $8.93.
ADAP has been the topic of a number of recent research reports. Cowen and Company reissued a “buy” rating on shares of Adaptimmune Therapeutics PLC in a report on Tuesday, June 6th. Zacks Investment Research raised shares of Adaptimmune Therapeutics PLC from a “hold” rating to a “buy” rating and set a $5.25 target price on the stock in a report on Wednesday, July 12th. BidaskClub raised shares of Adaptimmune Therapeutics PLC from a “sell” rating to a “hold” rating in a report on Sunday, July 16th. Leerink Swann reissued an “outperform” rating and issued a $15.00 target price on shares of Adaptimmune Therapeutics PLC in a report on Friday. Finally, ValuEngine raised shares of Adaptimmune Therapeutics PLC from a “strong sell” rating to a “sell” rating in a report on Thursday, July 20th. Two equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and three have assigned a buy rating to the company. Adaptimmune Therapeutics PLC has an average rating of “Hold” and a consensus target price of $12.08.
The firm’s market cap is $818.29 million. The firm’s 50 day moving average price is $5.70 and its 200-day moving average price is $5.18.
Adaptimmune Therapeutics PLC (NASDAQ:ADAP) last released its quarterly earnings results on Thursday, August 3rd. The biotechnology company reported ($0.24) EPS for the quarter, meeting the Zacks’ consensus estimate of ($0.24). The firm had revenue of $3.52 million for the quarter, compared to analyst estimates of $5.43 million. Adaptimmune Therapeutics PLC had a negative net margin of 438.00% and a negative return on equity of 38.73%. Equities analysts forecast that Adaptimmune Therapeutics PLC will post ($0.99) EPS for the current year.
A number of large investors have recently added to or reduced their stakes in ADAP. Raymond James Financial Services Advisors Inc. acquired a new position in Adaptimmune Therapeutics PLC in the first quarter valued at about $120,000. KCG Holdings Inc. acquired a new position in shares of Adaptimmune Therapeutics PLC during the first quarter worth approximately $133,000. Monashee Investment Management LLC acquired a new position in shares of Adaptimmune Therapeutics PLC during the first quarter worth approximately $138,000. OxFORD Asset Management LLP acquired a new position in shares of Adaptimmune Therapeutics PLC during the second quarter worth approximately $156,000. Finally, Paloma Partners Management Co acquired a new position in shares of Adaptimmune Therapeutics PLC during the first quarter worth approximately $165,000. Hedge funds and other institutional investors own 68.01% of the company’s stock.
Adaptimmune Therapeutics PLC Company Profile
Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. The Company has developed a platform that enables it to identify cancer targets, find and genetically engineer TCR, and produce TCR therapeutic candidates for administration to patients.
Receive News & Stock Ratings for Adaptimmune Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics PLC and related stocks with our FREE daily email newsletter.